Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Provided By GlobeNewswire
Last update: May 8, 2025
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 --
--Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --
Read more at globenewswire.comNASDAQ:VERU (12/18/2025, 5:20:02 PM)
2.26
+0.03 (+1.35%)
Find more stocks in the Stock Screener
